Compare Novartis with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PANACEA BIOTECH - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PANACEA BIOTECH NOVARTIS/
PANACEA BIOTECH
 
P/E (TTM) x 908.8 5.2 17,451.2% View Chart
P/BV x 27.3 2.0 1,347.2% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 NOVARTIS   PANACEA BIOTECH
EQUITY SHARE DATA
    NOVARTIS
Mar-19
PANACEA BIOTECH
Mar-19
NOVARTIS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs980354 277.1%   
Low Rs600138 434.3%   
Sales per share (Unadj.) Rs198.774.6 266.5%  
Earnings per share (Unadj.) Rs21.06.7 313.9%  
Cash flow per share (Unadj.) Rs22.315.5 143.6%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs307.557.2 537.5%  
Shares outstanding (eoy) m24.6961.25 40.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.03.3 120.6%   
Avg P/E ratio x37.736.8 102.4%  
P/CF ratio (eoy) x35.515.9 223.7%  
Price / Book Value ratio x2.64.3 59.8%  
Dividend payout %47.70-   
Avg Mkt Cap Rs m19,50815,061 129.5%   
No. of employees `0000.62.3 25.1%   
Total wages/salary Rs m1,1711,471 79.6%   
Avg. sales/employee Rs Th8,445.41,973.6 427.9%   
Avg. wages/employee Rs Th2,015.7635.6 317.1%   
Avg. net profit/employee Rs Th891.0176.8 504.0%   
INCOME DATA
Net Sales Rs m4,9074,567 107.4%  
Other income Rs m78345 1,746.9%   
Total revenues Rs m5,6894,612 123.4%   
Gross profit Rs m1232,030 6.1%  
Depreciation Rs m32540 5.9%   
Interest Rs m161,048 1.5%   
Profit before tax Rs m858486 176.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m34077 441.0%   
Profit after tax Rs m518409 126.5%  
Gross profit margin %2.544.4 5.6%  
Effective tax rate %39.615.9 250.0%   
Net profit margin %10.69.0 117.8%  
BALANCE SHEET DATA
Current assets Rs m8,0552,415 333.6%   
Current liabilities Rs m1,8509,077 20.4%   
Net working cap to sales %126.4-145.9 -86.7%  
Current ratio x4.40.3 1,636.7%  
Inventory Days Days4565 69.2%  
Debtors Days Days3471 47.8%  
Net fixed assets Rs m1508,333 1.8%   
Share capital Rs m12361 201.3%   
"Free" reserves Rs m7,4693,443 216.9%   
Net worth Rs m7,5923,504 216.7%   
Long term debt Rs m0461 0.0%   
Total assets Rs m9,82413,755 71.4%  
Interest coverage x54.91.5 3,753.5%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.50.3 150.4%   
Return on assets %5.410.6 51.3%  
Return on equity %6.811.7 58.4%  
Return on capital %11.538.7 29.7%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m581,203 4.8%   
Fx outflow Rs m1,326467 284.2%   
Net fx Rs m-1,269736 -172.3%   
CASH FLOW
From Operations Rs m-1,9431,049 -185.2%  
From Investments Rs m2,742-54 -5,125.8%  
From Financial Activity Rs m-298-1,011 29.5%  
Net Cashflow Rs m501-20 -2,544.7%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.6 333.3%  
FIIs % 1.6 1.3 123.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 23.6 91.1%  
Shareholders   41,647 10,259 406.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)

Indian stock markets mostly remained in the negative zone during the week except for Wednesday.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 20, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS